Kerry L. Cox

1.8k total citations
24 papers, 1.1k citations indexed

About

Kerry L. Cox is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kerry L. Cox has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 12 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Molecular Biology. Recurrent topics in Kerry L. Cox's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and T-cell and B-cell Immunology (8 papers). Kerry L. Cox is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and T-cell and B-cell Immunology (8 papers). Kerry L. Cox collaborates with scholars based in United Kingdom, United States and Netherlands. Kerry L. Cox's co-authors include Mark S. Cragg, Martin J. Glennie, H.T. Claude Chan, Stephen A. Beers, Ruth R. French, Peter Johnson, C. Ian Mockridge, Sean H. Lim, Sandra V. Dixon and Gill Rowlands and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Blood.

In The Last Decade

Kerry L. Cox

23 papers receiving 1.1k citations

Peers

Kerry L. Cox
Sean H. Lim United Kingdom
William Townsend United Kingdom
Pauline A. van Schouwenburg Netherlands
Michael Dechant Germany
Mehmet F. Fer United States
Bruce A. Robbins United States
Robert Wasserman United States
Daniel Ré Germany
Antonia Kwan United States
S Brown United States
Sean H. Lim United Kingdom
Kerry L. Cox
Citations per year, relative to Kerry L. Cox Kerry L. Cox (= 1×) peers Sean H. Lim

Countries citing papers authored by Kerry L. Cox

Since Specialization
Citations

This map shows the geographic impact of Kerry L. Cox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry L. Cox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry L. Cox more than expected).

Fields of papers citing papers by Kerry L. Cox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry L. Cox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry L. Cox. The network helps show where Kerry L. Cox may publish in the future.

Co-authorship network of co-authors of Kerry L. Cox

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry L. Cox. A scholar is included among the top collaborators of Kerry L. Cox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry L. Cox. Kerry L. Cox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oldham, Robert, Kerry L. Cox, Martin C. Taylor, et al.. (2025). FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs. Clinical & Experimental Immunology. 219(1). 1 indexed citations
2.
Foxall, Russell B., Kerry L. Cox, Robert Oldham, et al.. (2024). CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis. PubMed. 5(1). ltaf029–ltaf029.
3.
Yu, Xiaojie, Christian M. Orr, H.T. Claude Chan, et al.. (2023). Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 614(7948). 539–547. 71 indexed citations
4.
Roghanian, Ali, Robert Oldham, H.T. Claude Chan, et al.. (2022). FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell Reports. 40(3). 111099–111099. 16 indexed citations
5.
Cummin, Thomas, Kerry L. Cox, Graham Packham, et al.. (2020). BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Advances. 4(14). 3316–3328. 28 indexed citations
6.
Oldham, Robert, C. Ian Mockridge, Sonya James, et al.. (2020). FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion. Journal for ImmunoTherapy of Cancer. 8(1). e000619–e000619. 12 indexed citations
7.
Cox, Kerry L., Christine A. Penfold, Ruth R. French, et al.. (2018). Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific Reports. 8(1). 2278–2278. 30 indexed citations
8.
Herter, Sylvia, Laura S. Grosmaire, Christian Frey, et al.. (2018). The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. The Journal of Immunology. 200(7). 2304–2312. 14 indexed citations
9.
Dahal, Lekh N., Lang Dou, Khiyam Hussain, et al.. (2017). STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research. 77(13). 3619–3631. 59 indexed citations
10.
Johnston, Harvey E., Matthew Carter, Kerry L. Cox, et al.. (2017). Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures. Molecular & Cellular Proteomics. 16(3). 386–406. 14 indexed citations
11.
Klymenko, Tetyana, Johannes Bloehdorn, Jasmin Bahlo, et al.. (2017). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 32(2). 364–375. 22 indexed citations
12.
Carter, Matthew, Kerry L. Cox, Stuart J. Blakemore, et al.. (2016). PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia. 31(6). 1423–1433. 11 indexed citations
13.
Chan, H.T. Claude, Christine A. Penfold, Sonya James, et al.. (2016). Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment. Blood. 128(22). 3024–3024. 1 indexed citations
14.
Carter, Matthew, Kerry L. Cox, Stuart J. Blakemore, et al.. (2015). BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma. Cell Death and Differentiation. 23(2). 303–312. 9 indexed citations
15.
Blunt, Matthew D., Matthew Carter, Marta Larráyoz, et al.. (2015). The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model. Blood. 125(26). 4032–4041. 34 indexed citations
16.
Williams, Emily L., Alison L. Tutt, Stephen A. Beers, et al.. (2013). Immunotherapy Targeting Inhibitory Fcγ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization. The Journal of Immunology. 191(8). 4130–4140. 23 indexed citations
17.
Beers, Stephen A., Ruth R. French, H.T. Claude Chan, et al.. (2010). Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 115(25). 5191–5201. 241 indexed citations
18.
Иванов, А. В., Stephen A. Beers, Claire A. Walshe, et al.. (2009). Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. Journal of Clinical Investigation. 119(8). 2143–59. 142 indexed citations
19.
Ashworth, Mark, Kerry L. Cox, Radoslav Latinovic, et al.. (2005). Reply. Journal of Public Health. 27(2). 229–231. 8 indexed citations
20.
Ashworth, Mark, Kerry L. Cox, Radoslav Latinovic, et al.. (2004). Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database. Journal of Public Health. 26(3). 268–274. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sean H. Lim Breakdown of academic impact, for papers by William Townsend Breakdown of academic impact, for papers by Pauline A. van Schouwenburg Breakdown of academic impact, for papers by Michael Dechant Breakdown of academic impact, for papers by Mehmet F. Fer Breakdown of academic impact, for papers by Bruce A. Robbins Breakdown of academic impact, for papers by Robert Wasserman Breakdown of academic impact, for papers by Daniel Ré Breakdown of academic impact, for papers by Antonia Kwan Breakdown of academic impact, for papers by S Brown
Rankless by CCL
2026